{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T11:19:05Z","timestamp":1784200745764,"version":"3.55.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2022,3,29]],"date-time":"2022-03-29T00:00:00Z","timestamp":1648512000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1007\/s00277-022-04821-y","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T01:06:40Z","timestamp":1648602400000},"page":"1321-1331","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Single-agent 5-azacytidine as post-transplant maintenance in high-risk myeloid malignancies undergoing allogeneic hematopoietic cell transplantation"],"prefix":"10.1007","volume":"101","author":[{"given":"Kevin-James","family":"Wattebled","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elodie","family":"Drumez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Val\u00e9rie","family":"Coiteux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onardo","family":"Magro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha","family":"Srour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Chauvet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Quesnel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Duhamel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ibrahim","family":"Yakoub-Agha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1866-828X","authenticated-orcid":false,"given":"David","family":"Beauvais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,29]]},"reference":[{"key":"4821_CR1","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1038\/s41409-018-0171-z","volume":"53","author":"M Horowitz","year":"2018","unstructured":"Horowitz M, Schreiber H, Elder A et al (2018) Epidemiology and biology of relapse after stem cell transplantation. Bone Marrow Transplant 53:1379\u20131389. https:\/\/doi.org\/10.1038\/s41409-018-0171-z","journal-title":"Bone Marrow Transplant"},{"key":"4821_CR2","doi-asserted-by":"publisher","first-page":"1599","DOI":"10.1182\/blood-2011-08-375840","volume":"119","author":"C Schmid","year":"2012","unstructured":"Schmid C, Labopin M, Nagler A et al (2012) Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation. Blood 119:1599\u20131606. https:\/\/doi.org\/10.1182\/blood-2011-08-375840","journal-title":"Blood"},{"key":"4821_CR3","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.retram.2018.08.003","volume":"67","author":"A Caulier","year":"2019","unstructured":"Caulier A, Drumez E, Gauthier J et al (2019) Scoring system based on post-transplant complications in patients after allogeneic hematopoietic cell transplantation for myelodysplastic syndrome: a study from the SFGM-TC. Curr Res Transl Med 67:8\u201315. https:\/\/doi.org\/10.1016\/j.retram.2018.08.003","journal-title":"Curr Res Transl Med"},{"key":"4821_CR4","doi-asserted-by":"publisher","first-page":"2540","DOI":"10.1038\/sj.leu.2404828","volume":"21","author":"B Oran","year":"2007","unstructured":"Oran B, Giralt S, Couriel D et al (2007) Treatment of AML and MDS relapsing after reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation. Leukemia 21:2540\u20132544. https:\/\/doi.org\/10.1038\/sj.leu.2404828","journal-title":"Leukemia"},{"key":"4821_CR5","doi-asserted-by":"publisher","first-page":"6475","DOI":"10.1158\/1078-0432.CCR-20-3134","volume":"26","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Schmid C, Labopin M et al (2020) Evaluation of trends and prognosis over time in patients with AML relapsing after allogeneic hematopoietic cell transplant reveals improved survival for young patients in recent years. Clin Cancer Res Off J Am Assoc Cancer Res 26:6475\u20136482. https:\/\/doi.org\/10.1158\/1078-0432.CCR-20-3134","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"4821_CR6","doi-asserted-by":"publisher","first-page":"S84","DOI":"10.1016\/j.bulcan.2017.05.009","volume":"104","author":"N Yafour","year":"2017","unstructured":"Yafour N, Beckerich F, Bulabois CE et al (2017) Strat\u00e9gies pr\u00e9ventives et th\u00e9rapeutiques de la rechute apr\u00e8s allogreffe de cellules souches h\u00e9matopo\u00ef\u00e9tiques\u202f: recommandations de la Soci\u00e9t\u00e9 francophone de greffe de moelle et de th\u00e9rapie cellulaire (SFGM-TC). Bull Cancer (Paris) 104:S84\u2013S98. https:\/\/doi.org\/10.1016\/j.bulcan.2017.05.009","journal-title":"Bull Cancer (Paris)"},{"key":"4821_CR7","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/joim.12720","volume":"283","author":"C Craddock","year":"2018","unstructured":"Craddock C, Versluis J, Labopin M et al (2018) Distinct factors determine the kinetics of disease relapse in adults transplanted for acute myeloid leukaemia. J Intern Med 283:371\u2013379. https:\/\/doi.org\/10.1111\/joim.12720","journal-title":"J Intern Med"},{"key":"4821_CR8","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.retram.2017.06.001","volume":"65","author":"N Yafour","year":"2017","unstructured":"Yafour N, Beckerich F, Bulabois CE et al (2017) How to prevent relapse after allogeneic hematopoietic stem cell transplantation in patients with acute leukemia and myelodysplastic syndrome. Curr Res Transl Med 65:65\u201369. https:\/\/doi.org\/10.1016\/j.retram.2017.06.001","journal-title":"Curr Res Transl Med"},{"key":"4821_CR9","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1038\/s41409-018-0269-3","volume":"54","author":"Y-B Chen","year":"2019","unstructured":"Chen Y-B, McCarthy PL, Hahn T et al (2019) Methods to prevent and treat relapse after hematopoietic stem cell transplantation with tyrosine kinase inhibitors, immunomodulating drugs, deacetylase inhibitors, and hypomethylating agents. Bone Marrow Transplant 54:497\u2013507. https:\/\/doi.org\/10.1038\/s41409-018-0269-3","journal-title":"Bone Marrow Transplant"},{"key":"4821_CR10","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1038\/s41409-018-0286-2","volume":"54","author":"CJ Lee","year":"2019","unstructured":"Lee CJ, Savani BN, Mohty M et al (2019) Post-remission strategies for the prevention of relapse following allogeneic hematopoietic cell transplantation for high-risk acute myeloid leukemia: expert review from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplant 54:519\u2013530. https:\/\/doi.org\/10.1038\/s41409-018-0286-2","journal-title":"Bone Marrow Transplant"},{"key":"4821_CR11","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1182\/blood-2009-12-257253","volume":"116","author":"J Choi","year":"2010","unstructured":"Choi J, Ritchey J, Prior JL et al (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116:129\u2013139. https:\/\/doi.org\/10.1182\/blood-2009-12-257253","journal-title":"Blood"},{"key":"4821_CR12","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood-2011-09-377044","volume":"119","author":"OC Goodyear","year":"2012","unstructured":"Goodyear OC, Dennis M, Jilani NY et al (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 119:3361\u20133369. https:\/\/doi.org\/10.1182\/blood-2011-09-377044","journal-title":"Blood"},{"key":"4821_CR13","doi-asserted-by":"publisher","first-page":"e1314425","DOI":"10.1080\/2162402X.2017.1314425","volume":"6","author":"G Ehx","year":"2017","unstructured":"Ehx G, Fransolet G, de Leval L et al (2017) Azacytidine prevents experimental xenogeneic graft-versus-host disease without abrogating graft-versus-leukemia effects. OncoImmunology 6:e1314425. https:\/\/doi.org\/10.1080\/2162402X.2017.1314425","journal-title":"OncoImmunology"},{"key":"4821_CR14","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nrd1698","volume":"4","author":"J-PJ Issa","year":"2005","unstructured":"Issa J-PJ, Kantarjian HM, Kirkpatrick P (2005) Azacitidine. Nat Rev Drug Discov 4:275\u2013276. https:\/\/doi.org\/10.1038\/nrd1698","journal-title":"Nat Rev Drug Discov"},{"key":"4821_CR15","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/nrg.2016.93","volume":"17","author":"PA Jones","year":"2016","unstructured":"Jones PA, Issa J-PJ, Baylin S (2016) Targeting the cancer epigenome for therapy. Nat Rev Genet 17:630\u2013641. https:\/\/doi.org\/10.1038\/nrg.2016.93","journal-title":"Nat Rev Genet"},{"key":"4821_CR16","doi-asserted-by":"publisher","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","volume":"20","author":"LR Silverman","year":"2002","unstructured":"Silverman LR, Demakos EP, Peterson BL et al (2002) Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B. J Clin Oncol 20:2429\u20132440. https:\/\/doi.org\/10.1200\/JCO.2002.04.117","journal-title":"J Clin Oncol"},{"key":"4821_CR17","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","volume":"10","author":"P Fenaux","year":"2009","unstructured":"Fenaux P, Mufti GJ, Hellstrom-Lindberg E et al (2009) Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol 10:223\u2013232. https:\/\/doi.org\/10.1016\/S1470-2045(09)70003-8","journal-title":"Lancet Oncol"},{"key":"4821_CR18","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1200\/JCO.2009.23.8329","volume":"28","author":"P Fenaux","year":"2010","unstructured":"Fenaux P, Mufti GJ, Hellstr\u00f6m-Lindberg E et al (2010) Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562\u2013569. https:\/\/doi.org\/10.1200\/JCO.2009.23.8329","journal-title":"J Clin Oncol"},{"key":"4821_CR19","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","volume":"126","author":"H Dombret","year":"2015","unstructured":"Dombret H, Seymour JF, Butrym A et al (2015) International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood 126:291\u2013299. https:\/\/doi.org\/10.1182\/blood-2015-01-621664","journal-title":"Blood"},{"key":"4821_CR20","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1182\/blood-2008-05-158956","volume":"113","author":"L Hambach","year":"2009","unstructured":"Hambach L, Ling K-W, Pool J et al (2009) Hypomethylating drugs convert HA-1\u2013negative solid tumors into targets for stem cell\u2013based immunotherapy. Blood 113:2715\u20132722. https:\/\/doi.org\/10.1182\/blood-2008-05-158956","journal-title":"Blood"},{"key":"4821_CR21","doi-asserted-by":"publisher","first-page":"1908","DOI":"10.1182\/blood-2009-11-249474","volume":"116","author":"O Goodyear","year":"2010","unstructured":"Goodyear O, Agathanggelou A, Novitzky-Basso I et al (2010) Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood 116:1908\u20131918. https:\/\/doi.org\/10.1182\/blood-2009-11-249474","journal-title":"Blood"},{"key":"4821_CR22","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1016\/j.leukres.2010.02.004","volume":"34","author":"M Almstedt","year":"2010","unstructured":"Almstedt M, Blagitko-Dorfs N, Duque-Afonso J et al (2010) The DNA demethylating agent 5-aza-2\u2032-deoxycytidine induces expression of NY-ESO-1 and other cancer\/testis antigens in myeloid leukemia cells. Leuk Res 34:899\u2013905. https:\/\/doi.org\/10.1016\/j.leukres.2010.02.004","journal-title":"Leuk Res"},{"key":"4821_CR23","doi-asserted-by":"publisher","first-page":"974","DOI":"10.1016\/j.cell.2015.07.011","volume":"162","author":"KB Chiappinelli","year":"2015","unstructured":"Chiappinelli KB, Strissel PL, Desrichard A et al (2015) Inhibiting DNA methylation causes an interferon response in cancer via dsRNA including endogenous retroviruses. Cell 162:974\u2013986. https:\/\/doi.org\/10.1016\/j.cell.2015.07.011","journal-title":"Cell"},{"key":"4821_CR24","doi-asserted-by":"publisher","first-page":"961","DOI":"10.1016\/j.cell.2015.07.056","volume":"162","author":"D Roulois","year":"2015","unstructured":"Roulois D, Loo Yau H, Singhania R et al (2015) DNA-demethylating agents target colorectal cancer cells by inducing viral mimicry by endogenous transcripts. Cell 162:961\u2013973. https:\/\/doi.org\/10.1016\/j.cell.2015.07.056","journal-title":"Cell"},{"key":"4821_CR25","doi-asserted-by":"publisher","first-page":"4644","DOI":"10.1182\/blood-2002-11-3458","volume":"101","author":"L Sigalotti","year":"2003","unstructured":"Sigalotti L, Altomonte M, Colizzi F et al (2003) 5-Aza-2\u2032-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach? Blood 101:4644\u20134646. https:\/\/doi.org\/10.1182\/blood-2002-11-3458","journal-title":"Blood"},{"key":"4821_CR26","doi-asserted-by":"publisher","first-page":"5420","DOI":"10.1002\/cncr.25500","volume":"116","author":"M de Lima","year":"2010","unstructured":"de Lima M, Giralt S, Thall PF et al (2010) Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer 116:5420\u20135431. https:\/\/doi.org\/10.1002\/cncr.25500","journal-title":"Cancer"},{"key":"4821_CR27","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1111\/bjh.13248","volume":"169","author":"G Oshikawa","year":"2015","unstructured":"Oshikawa G, Kakihana K, Saito M et al (2015) Post-transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for high-risk acute myeloid leukaemia. Br J Haematol 169:756\u2013759. https:\/\/doi.org\/10.1111\/bjh.13248","journal-title":"Br J Haematol"},{"key":"4821_CR28","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.bbmt.2015.09.004","volume":"22","author":"C Craddock","year":"2016","unstructured":"Craddock C, Jilani N, Siddique S et al (2016) Tolerability and clinical activity of post-transplantation azacitidine in patients allografted for acute myeloid leukemia treated on the RICAZA Trial. Biol Blood Marrow Transplant 22:385\u2013390. https:\/\/doi.org\/10.1016\/j.bbmt.2015.09.004","journal-title":"Biol Blood Marrow Transplant"},{"key":"4821_CR29","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1038\/bmt.2017.31","volume":"52","author":"J El-Cheikh","year":"2017","unstructured":"El-Cheikh J, Massoud R, Fares E et al (2017) Low-dose 5-azacytidine as preventive therapy for relapse of AML and MDS following allogeneic HCT. Bone Marrow Transplant 52:918\u2013921. https:\/\/doi.org\/10.1038\/bmt.2017.31","journal-title":"Bone Marrow Transplant"},{"key":"4821_CR30","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.bbmt.2018.06.016","volume":"24","author":"M de Lima","year":"2018","unstructured":"de Lima M, Oran B, Champlin RE et al (2018) CC-486 Maintenance after stem cell transplantation in patients with acute myeloid leukemia or myelodysplastic syndromes. Biol Blood Marrow Transplant 24:2017\u20132024. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.016","journal-title":"Biol Blood Marrow Transplant"},{"key":"4821_CR31","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1038\/s41409-019-0536-y","volume":"54","author":"T Guillaume","year":"2019","unstructured":"Guillaume T, Malard F, Magro L et al (2019) Prospective phase II study of prophylactic low-dose azacitidine and donor lymphocyte infusions following allogeneic hematopoietic stem cell transplantation for high-risk acute myeloid leukemia and myelodysplastic syndrome. Bone Marrow Transplant 54:1815\u20131826. https:\/\/doi.org\/10.1038\/s41409-019-0536-y","journal-title":"Bone Marrow Transplant"},{"key":"4821_CR32","doi-asserted-by":"publisher","first-page":"2836","DOI":"10.1080\/10428194.2018.1443334","volume":"59","author":"KT Maples","year":"2018","unstructured":"Maples KT, Sabo RT, McCarty JM et al (2018) Maintenance azacitidine after myeloablative allogeneic hematopoietic cell transplantation for myeloid malignancies. Leuk Lymphoma 59:2836\u20132841. https:\/\/doi.org\/10.1080\/10428194.2018.1443334","journal-title":"Leuk Lymphoma"},{"key":"4821_CR33","doi-asserted-by":"publisher","first-page":"5580","DOI":"10.1182\/bloodadvances.2020002544","volume":"4","author":"B Oran","year":"2020","unstructured":"Oran B, de Lima M, Garcia-Manero G et al (2020) A phase 3 randomized study of 5-azacitidine maintenance vs observation after transplant in high-risk AML and MDS patients. Blood Adv 4:5580\u20135588. https:\/\/doi.org\/10.1182\/bloodadvances.2020002544","journal-title":"Blood Adv"},{"key":"4821_CR34","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1002\/acg2.30","volume":"2","author":"T Schroeder","year":"2019","unstructured":"Schroeder T, Rautenberg C, Haas R et al (2019) Do hypomethylating agents prevent relapse after Allo-HCT? Adv Cell Gene Ther 2:e30. https:\/\/doi.org\/10.1002\/acg2.30","journal-title":"Adv Cell Gene Ther"},{"key":"4821_CR35","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1182\/blood-2018-99-112614","volume":"132","author":"A Burchert","year":"2018","unstructured":"Burchert A, Bug G, Finke J et al (2018) Sorafenib As maintenance therapy post allogeneic stem cell transplantation for FLT3-ITD positive AML: results from the randomized, double-blind, placebo-controlled multicentre sormain trial. Blood 132:661\u2013661. https:\/\/doi.org\/10.1182\/blood-2018-99-112614","journal-title":"Blood"},{"key":"4821_CR36","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.3324\/haematol.2019.243410","volume":"105","author":"A Bazarbachi","year":"2020","unstructured":"Bazarbachi A, Bug G, Baron F et al (2020) Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Haematologica 105:1507\u20131516. https:\/\/doi.org\/10.3324\/haematol.2019.243410","journal-title":"Haematologica"},{"key":"4821_CR37","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-020-0803-y","author":"A Spyridonidis","year":"2020","unstructured":"Spyridonidis A, Labopin M, Savani BN et al (2020) Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients. Bone Marrow Transplant. https:\/\/doi.org\/10.1038\/s41409-020-0803-y","journal-title":"Bone Marrow Transplant"},{"key":"4821_CR38","doi-asserted-by":"publisher","first-page":"541","DOI":"10.2307\/2530374","volume":"34","author":"RL Prentice","year":"1978","unstructured":"Prentice RL, Kalbfleisch JD, Peterson AV et al (1978) The analysis of failure times in the presence of competing risks. Biometrics 34:541. https:\/\/doi.org\/10.2307\/2530374","journal-title":"Biometrics"},{"key":"4821_CR39","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine JP, Gray RJ (1999) A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 94:496\u2013509. https:\/\/doi.org\/10.1080\/01621459.1999.10474144","journal-title":"J Am Stat Assoc"},{"key":"4821_CR40","doi-asserted-by":"publisher","first-page":"239","DOI":"10.2307\/2335876","volume":"69","author":"D Schoenfeld","year":"1982","unstructured":"Schoenfeld D (1982) Partial residuals for the proportional hazards regression model. Biometrika 69:239\u2013241. https:\/\/doi.org\/10.2307\/2335876","journal-title":"Biometrika"},{"key":"4821_CR41","doi-asserted-by":"publisher","first-page":"4249","DOI":"10.1200\/JCO.19.03277","volume":"38","author":"L Gao","year":"2020","unstructured":"Gao L, Zhang Y, Wang S et al (2020) Effect of rhG-CSF combined with decitabine prophylaxis on relapse of patients with high-risk MRD-negative AML after HSCT: An Open-Label, Multicenter, Randomized Controlled Trial. J Clin Oncol Off J Am Soc Clin Oncol 38:4249\u20134259. https:\/\/doi.org\/10.1200\/JCO.19.03277","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"4821_CR42","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1016\/S1470-2045(18)30580-1","volume":"19","author":"U Platzbecker","year":"2018","unstructured":"Platzbecker U, Middeke JM, Sockel K et al (2018) Measurable residual disease-guided treatment with azacitidine to prevent haematological relapse in patients with myelodysplastic syndrome and acute myeloid leukaemia (RELAZA2): an open-label, multicentre, phase 2 trial. Lancet Oncol 19:1668\u20131679. https:\/\/doi.org\/10.1016\/S1470-2045(18)30580-1","journal-title":"Lancet Oncol"},{"key":"4821_CR43","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/leu.2011.234","volume":"26","author":"U Platzbecker","year":"2012","unstructured":"Platzbecker U, Wermke M, Radke J et al (2012) Azacitidine for treatment of imminent relapse in MDS or AML patients after allogeneic HSCT: results of the RELAZA trial. Leukemia 26:381\u2013389. https:\/\/doi.org\/10.1038\/leu.2011.234","journal-title":"Leukemia"},{"key":"4821_CR44","doi-asserted-by":"publisher","first-page":"1984","DOI":"10.1016\/j.bbmt.2019.06.007","volume":"25","author":"R Vij","year":"2019","unstructured":"Vij R, Le-Rademacher J, Laumann K et al (2019) A phase II multicenter study of the addition of azacitidine to reduced-intensity conditioning allogeneic transplant for high-risk myelodysplasia (and older patients with acute myeloid leukemia): results of CALGB 100801 (Alliance). Biol Blood Marrow Transplant 25:1984\u20131992. https:\/\/doi.org\/10.1016\/j.bbmt.2019.06.007","journal-title":"Biol Blood Marrow Transplant"},{"key":"4821_CR45","doi-asserted-by":"publisher","unstructured":"Ali N, Tomlinson B, Metheny L et al (2020) Conditioning regimen intensity and low-dose azacitidine maintenance after allogeneic hematopoietic cell transplantation for acute myeloid leukemia. Leuk Lymphoma 61(12):2839\u20132849.\u00a0https:\/\/doi.org\/10.1080\/10428194.2020.1789630","DOI":"10.1080\/10428194.2020.1789630"},{"key":"4821_CR46","doi-asserted-by":"publisher","first-page":"LBA-3","DOI":"10.1182\/blood-2019-132405","volume":"134","author":"AH Wei","year":"2019","unstructured":"Wei AH, D\u00f6hner H, Pocock C et al (2019) The QUAZAR AML-001 maintenance trial: results of a phase III international, randomized, double-blind, placebo-controlled study of CC-486 (oral formulation of azacitidine) in patients with acute myeloid leukemia (AML) in first remission. Blood 134:LBA-3. https:\/\/doi.org\/10.1182\/blood-2019-132405","journal-title":"Blood"},{"key":"4821_CR47","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28:1280\u20131288. https:\/\/doi.org\/10.1038\/leu.2013.355","journal-title":"Leukemia"},{"key":"4821_CR48","doi-asserted-by":"publisher","unstructured":"\u00d8rskov AD, Treppendahl MB, Skovbo A et al (2015) Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: A rationale for combined targeting of PD-1 and DNA methylation. Oncotarget\u00a06(11):9612\u201326.\u00a0https:\/\/doi.org\/10.18632\/oncotarget.3324","DOI":"10.18632\/oncotarget.3324"},{"key":"4821_CR49","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1186\/s13045-020-00853-x","volume":"13","author":"C Chen","year":"2020","unstructured":"Chen C, Liang C, Wang S et al (2020) Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol OncolJ Hematol Oncol 13:28. https:\/\/doi.org\/10.1186\/s13045-020-00853-x","journal-title":"J Hematol OncolJ Hematol Oncol"},{"key":"4821_CR50","doi-asserted-by":"publisher","first-page":"236","DOI":"10.3390\/jcm8020236","volume":"8","author":"K Giannopoulos","year":"2019","unstructured":"Giannopoulos K (2019) Targeting immune signaling checkpoints in acute myeloid leukemia. J Clin Med 8:236. https:\/\/doi.org\/10.3390\/jcm8020236","journal-title":"J Clin Med"},{"key":"4821_CR51","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood.V130.Suppl_1.815.815","volume":"130","author":"F Ravandi","year":"2017","unstructured":"Ravandi F, Daver N, Garcia-Manero G et al (2017) Phase 2 study of combination of cytarabine, idarubicin, and nivolumab for initial therapy of patients with newly diagnosed acute myeloid leukemia. Blood 130:815\u2013815. https:\/\/doi.org\/10.1182\/blood.V130.Suppl_1.815.815","journal-title":"Blood"},{"key":"4821_CR52","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S et al (2019) Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov 9:370\u2013383. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-0774","journal-title":"Cancer Discov"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-022-04821-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-022-04821-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,5]],"date-time":"2022-05-05T10:09:02Z","timestamp":1651745342000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-022-04821-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,29]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["4821"],"URL":"https:\/\/doi.org\/10.1007\/s00277-022-04821-y","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,29]]},"assertion":[{"value":"30 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Informed consent was obtained from all patients for being included in the study. This study was led according to the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}